{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:21:18Z","timestamp":1787959278267,"version":"build-2784847793"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08189-9","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:25:58Z","timestamp":1777371958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dual immunosuppression mechanism induced by PTP1B in colorectal cancer: upregulation of PD-L1 by FOXO1\/miR-34C\/c-MYC axis and inhibition of the infiltration of CD8(+) T cell by downregulating of CXCL11"],"prefix":"10.1186","volume":"24","author":[{"given":"Zihan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianshuo","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2955-0770","authenticated-orcid":false,"given":"Jian","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"issue":"3","key":"8189_CR1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3760\/cma.j.cn112152-20240119-00035","volume":"46","author":"RS Zheng","year":"2024","unstructured":"Zheng RS, Chen R, Han BF, Wang SM, Li L, Sun KX, et al. [Cancer incidence and mortality in China, 2022]. Zhonghua Zhong Liu Za Zhi. 2024 Mar 23;46(3):221\u201331. Chinese. https:\/\/doi.org\/10.3760\/cma.j.cn112152-20240119-00035. PMID: 38468501.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"143","key":"8189_CR2","doi-asserted-by":"publisher","first-page":"113365","DOI":"10.1016\/j.intimp.2024.113365","volume":"143","author":"M Arafat Hossain","year":"2024","unstructured":"Arafat Hossain M. A comprehensive review of immune checkpoint inhibitors for cancer treatment. Int Immunopharmacol. 2024, Dec;143(143):113365. https:\/\/doi.org\/10.1016\/j.intimp.2024.113365. Epub 2024 Oct 23. PMID: 39447408.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"8189_CR3","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3390\/cells12020258","volume":"12","author":"I Yu","year":"2023","unstructured":"Yu I, Dakwar A, Takabe K. Immunotherapy: recent advances and its future as a neoadjuvant, adjuvant, and primary treatment in colorectal cancer. Cells. 2023, Jan, 8;12(2):258. https:\/\/doi.org\/10.3390\/cells12020258. PMID: 36672193; PMCID: PMC9856401.","journal-title":"Cells"},{"issue":"4","key":"8189_CR4","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s12029-023-00927-2","volume":"54","author":"J El Hajj","year":"2023","unstructured":"El Hajj J, Reddy S, Verma N, Huang EH, Kazmi SM. Immune checkpoint inhibitors in pMMR\/MSS colorectal cancer. J Gastrointest Cancer. 2023, Dec;54(4):1017\u201330. https:\/\/doi.org\/10.1007\/s12029-023-00927-2. Epub 2023 Apr 3. PMID: 37009977.","journal-title":"J Gastrointest Cancer"},{"issue":"6","key":"8189_CR5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1634\/theoncologist.2019-0611","volume":"25","author":"F Loupakis","year":"2020","unstructured":"Loupakis F, Depetris I, Biason P, Intini R, Prete AA, Leone F, et al. Prediction of benefit from checkpoint inhibitors in mismatch repair deficient metastatic colorectal cancer: role of tumor infiltrating lymphocytes. The Oncologist. 2020, Jun;25(6):481\u201387. https:\/\/doi.org\/10.1634\/theoncologist.2019-0611. Epub 2020 Jan 22. PMID: 31967692; PMCID: PMC7288636.","journal-title":"The Oncologist"},{"key":"8189_CR6","doi-asserted-by":"publisher","unstructured":"Ke H, Li Z, Li P, Ye S, Huang J, Hu T, et al. Dynamic heterogeneity of colorectal cancer during progression revealed clinical risk-associated cell types and regulations in single-cell resolution and spatial context. Gastroenterol Rep. 2022, Jun, 24;11:goad034. https:\/\/doi.org\/10.1093\/gastro\/goad034. PMID: 37360193; PMCID: PMC10290555.","DOI":"10.1093\/gastro\/goad034"},{"issue":"1","key":"8189_CR7","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/JS9.0000000000003459","volume":"112","author":"Y Chen","year":"2026","unstructured":"Chen Y, Liu T, Min G, Wang C, Xi D, Jiang L. Single-cell transcriptome analysis reveals regulatory programs associated with tumor resistance during immunotherapy in colorectal cancer. Int J Surg. 2026, Jan, 1;112(1):694\u2013708. https:\/\/doi.org\/10.1097\/JS9.0000000000003459. 2025 Sep 9. PMID: 40932376; PMCID: PMC12825545.","journal-title":"Int J Surg"},{"key":"8189_CR8","doi-asserted-by":"publisher","unstructured":"Ke H, Li P, Li Z, Zeng X, Zhang C, Luo S, et al. Immune profiling of the macroenvironment in colorectal cancer unveils systemic dysfunction and plasticity of immune cells. Clin Transl Med. 2025, Feb;15(2):e70175. https:\/\/doi.org\/10.1002\/ctm2.70175. PMID: 39934971; PMCID: PMC11813809.","DOI":"10.1002\/ctm2.70175"},{"issue":"1","key":"8189_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41422-025-01206-4","volume":"36","author":"W Ma","year":"2026","unstructured":"Ma W, Li W, Chen T, Jing L, Chen Y, Li K, et al. Targeting PTPN13 with 11-amino-acid peptides of C-terminal APC prevents immune evasion of colorectal cancer. Cell Res. 2026, Jan;36(1):72\u201393. https:\/\/doi.org\/10.1038\/s41422-025-01206-4. 2026 Jan 5. PMID: 41486293; PMCID: PMC12765898.","journal-title":"Cell Res"},{"issue":"155","key":"8189_CR10","doi-asserted-by":"publisher","first-page":"114579","DOI":"10.1016\/j.intimp.2025.114579","volume":"155","author":"J Liu","year":"2025","unstructured":"Liu J, Su Y, Zhang C, Dong H, Yu R, Yang X, et al. NCOA3 impairs the efficacy of anti-PD-L1 therapy via HSP90\u03b1\/EZH2\/CXCL9 axis in colon cancer. Int Immunopharmacol. 2025, May;155(155):114579. https:\/\/doi.org\/10.1016\/j.intimp.2025.114579. 2025 Apr 10. PMID: 40215778.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"8189_CR11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41419-026-08413-w","volume":"17","author":"X Zhang","year":"2026","unstructured":"Zhang X, Fei Y, Xie C, Li T, Niu B, Yang Z, et al. Cancer-associated fibroblasts (CAFs) derived from MFAP2 promote CRC proliferation and metastasis while suppressing CD8+ T cell-mediated antitumor immunity. Cell Death Dis. 2026, Jan, 30;17(1):159. https:\/\/doi.org\/10.1038\/s41419-026-08413-w. PMID: 41617683; PMCID: PMC12877200.","journal-title":"Cell Death Dis"},{"issue":"15","key":"8189_CR12","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1002\/1873-3468.14901","volume":"598","author":"A Coronell-Tovar","year":"2024","unstructured":"Coronell-Tovar A, Pardo JP, Rodr\u00edguez-Romero A, Sosa-Peinado A, V\u00e1squez-Bochm L, Cano-S\u00e1nchez P, et al. Protein tyrosine phosphatase 1B (PTP1B) function, structure, and inhibition strategies to develop antidiabetic drugs. FEBS Lett. 2024, Aug;598(15):1811\u201338. https:\/\/doi.org\/10.1002\/1873-3468.14901. Epub 2024 May 9. PMID: 38724486.","journal-title":"FEBS Lett"},{"issue":"Pt 3","key":"8189_CR13","doi-asserted-by":"publisher","first-page":"144848","DOI":"10.1016\/j.ijbiomac.2025.144848","volume":"318","author":"S Yoon","year":"2025","unstructured":"Yoon S, Cho J, Kim J, Kim KD, Kang YJ. Structure-based discovery and conformational analysis of non-phosphomimetic bidentate inhibitor for protein tyrosine phosphatase 1B. Int J Biol Macromolecules. 2025, Jul;318(Pt 3):144848. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.144848. Epub 2025 Jun 6. PMID: 40484072.","journal-title":"Int J Biol Macromolecules"},{"issue":"3","key":"8189_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2174\/1568009622666220128113400","volume":"22","author":"PJ Chen","year":"2022","unstructured":"Chen PJ, Zhang YT. Protein tyrosine phosphatase 1B (PTP1B): insights into its new implications in tumorigenesis. CCDT. 2022;22(3):181\u201394. https:\/\/doi.org\/10.2174\/1568009622666220128113400. PMID: 35088671.","journal-title":"CCDT"},{"issue":"1","key":"8189_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/imcb.12516","volume":"100","author":"RJ Salmond","year":"2022","unstructured":"Salmond RJ. Unleashing T cell responses to cancer through removal of intracellular checkpoints. Immunol Cell Biol. 2022, Jan;100(1):18\u201320. https:\/\/doi.org\/10.1111\/imcb.12516. Epub 2021 Dec 21. PMID: 34936141.","journal-title":"Immunol Cell Biol"},{"issue":"7","key":"8189_CR16","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/s41591-018-0023-9","volume":"24","author":"S Mainardi","year":"2018","unstructured":"Mainardi S, Mulero-S\u00e1nchez A, Prahallad A, Germano G, Bosma A, Krimpenfort P, et al. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. Nat Med. 2018, Jul;24(7):961\u201367. https:\/\/doi.org\/10.1038\/s41591-018-0023-9. Epub 2018 May 28. PMID: 29808006.","journal-title":"Nat Med"},{"key":"8189_CR17","doi-asserted-by":"publisher","unstructured":"Zhou J, Guo H, Zhang Y, Liu H, Dou Q. The role of PTP1B (PTPN1) in the prognosis of solid tumors: a meta-analysis. Med (Baltim). 2022, Oct, 7;101(40):e30826. https:\/\/doi.org\/10.1097\/MD.0000000000030826. PMID: 36221386; PMCID: PMC9543024.","DOI":"10.1097\/MD.0000000000030826"},{"issue":"21","key":"8189_CR18","doi-asserted-by":"publisher","first-page":"10129","DOI":"10.1158\/0008-5472.CAN-06-4338","volume":"67","author":"S Zhu","year":"2007","unstructured":"Zhu S, Bjorge JD, Fujita DJ. PTP1B contributes to the oncogenic properties of colon cancer cells through src activation. Cancer Res. 2007, Nov, 1;67(21):10129\u201337. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-4338. PMID: 17974954.","journal-title":"Cancer Res"},{"issue":"3","key":"8189_CR19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1084\/jem.20131196","volume":"211","author":"D Medgyesi","year":"2014","unstructured":"Medgyesi D, Hobeika E, Biesen R, Kollert F, Taddeo A, Voll RE, et al. The protein tyrosine phosphatase PTP1B is a negative regulator of CD40 and BAFF-R signaling and controls B cell autoimmunity. J Exp Med. 2014, Mar, 10;211(3):427\u201340. https:\/\/doi.org\/10.1084\/jem.20131196. Epub 2014 Mar 3. PMID: 24590766; PMCID: PMC3949573.","journal-title":"J Exp Med"},{"key":"8189_CR20","doi-asserted-by":"publisher","first-page":"1364778","DOI":"10.3389\/fmed.2024.1364778","volume":"11","author":"LA Perez-Quintero","year":"2024","unstructured":"Perez-Quintero LA, Abidin BM, Tremblay ML. Immunotherapeutic implications of negative regulation by protein tyrosine phosphatases in T cells: the emerging cases of PTP1B and TCPTP. Front. Med. 2024, Apr, 19;11:1364778. https:\/\/doi.org\/10.3389\/fmed.2024.1364778. PMID: 38707187; PMCID: PMC11066278.","journal-title":"Front. Med"},{"key":"8189_CR21","doi-asserted-by":"publisher","unstructured":"Li M, Zhao X, Wu J, Zhou S, Fu Y, Chen C, et al. Targeting the N-acetyltransferase 10\/DKK2 axis enhances CD8+ T cell antitumor activity in colorectal cancer models. J Clin Investigation. 2026, Jan, 16;136(2):e196722. https:\/\/doi.org\/10.1172\/JCI196722. PMID: 41542770; PMCID: PMC12807479.","DOI":"10.1172\/JCI196722"},{"issue":"3","key":"8189_CR22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/13543776.2026.2621091","volume":"36","author":"R Ashfaq","year":"2026","unstructured":"Ashfaq R, Hussain H. Protein tyrosine phosphatase 1B (PTP1B) inhibitors as potential anti-diabetes agents: updated patent review (2019\u20132023). Expert Opin Ther Pat. 2026, Mar;36(3):203\u201324. https:\/\/doi.org\/10.1080\/13543776.2026.2621091. Epub 2026 Jan 30. PMID: 41565465.","journal-title":"Expert Opin Ther Pat"},{"issue":"295","key":"8189_CR23","doi-asserted-by":"publisher","first-page":"117791","DOI":"10.1016\/j.ejmech.2025.117791","volume":"295","author":"AS Haider","year":"2025","unstructured":"Haider AS, Ambatwar R, Khatik GL. Insights into PTP1B inhibitors as antidiabetic agents: current research and future perspectives. Eur J Criminol Med Chem. 2025, Oct;295(295):117791. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117791. Epub 2025 May 23. PMID: 40460723.","journal-title":"Eur J Criminol Med Chem"},{"issue":"3","key":"8189_CR24","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/2159-8290.CD-21-0694","volume":"12","author":"F Wiede","year":"2022","unstructured":"Wiede F, Lu KH, Du X, Zeissig MN, Xu R, Goh PK, et al. PTP1B is an intracellular checkpoint that limits T-cell and CAR T-cell antitumor immunity. Cancer Discov. 2022, Mar, 1;12(3):752\u201373. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0694. PMID: 34794959; PMCID: PMC8904293.","journal-title":"Cancer Discov"},{"issue":"1","key":"8189_CR25","doi-asserted-by":"publisher","first-page":"4524","DOI":"10.1038\/s41467-023-40170-8","volume":"14","author":"S Liang","year":"2023","unstructured":"Liang S, Tran E, Du X, Dong J, Sudholz H, Chen H, et al. A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity. Nat Commun. 2023, Jul, 27;14(1):4524. https:\/\/doi.org\/10.1038\/s41467-023-40170-8. PMID: 37500611; PMCID: PMC10374545.","journal-title":"Nat Commun"},{"key":"8189_CR26","doi-asserted-by":"publisher","unstructured":"Peng M, Lu X, Guo J, Yin X, Zhang J, Li X, et al. A pair of promising immune checkpoints PSGL-1 and VISTA from immunotolerance to immunotherapy. Biomark Res. 12(1):151. https:\/\/doi.org\/10.1186\/s40364-024-00693-8. 2024 Dec 2 in:Biomark Res.2025Jan 23; 13(1):19.doi 10.1186\/s40364-024-00709-3. PMID: 39617949; PMCID: PMC11610313.","DOI":"10.1186\/s40364-024-00693-8"},{"issue":"10","key":"8189_CR27","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3389\/fphar.2019.00421","volume":"10","author":"X Huang","year":"2019","unstructured":"Huang X, Sun J, Chen G, Niu C, Wang Y, Zhao C, et al. Resveratrol promotes diabetic wound healing via SIRT1-FOXO1-c-Myc signaling pathway-mediated angiogenesis. Front Pharmacol. 2019, Apr;10(10):421. https:\/\/doi.org\/10.3389\/fphar.2019.00421. PMID: 31068817; PMCID: PMC6491521.","journal-title":"Front Pharmacol"},{"issue":"9","key":"8189_CR28","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.trecan.2025.04.016","volume":"11","author":"N Goto","year":"2025","unstructured":"Goto N, Agudo J, Yilmaz \u00d6H. Early immune evasion in colorectal cancer: interplay between stem cells and the tumor microenvironment. Trends Cancer. 2025, Sep;11(9):850\u201361. https:\/\/doi.org\/10.1016\/j.trecan.2025.04.016. Epub 2025 May 16. PMID: 40382216.","journal-title":"Trends Cancer"},{"issue":"2","key":"8189_CR29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10735-013-9536-1","volume":"45","author":"Q Chen","year":"2014","unstructured":"Chen Q, Li Y, Li Z, Zhao Q, Fan L. Overexpression of PTP1B in human colorectal cancer and its association with tumor progression and prognosis. J Mol Histol. 2014, Apr;45(2):153\u201359. https:\/\/doi.org\/10.1007\/s10735-013-9536-1. Epub 2013 Aug 29. PMID: 23990346.","journal-title":"J Mol Histol"},{"issue":"5","key":"8189_CR30","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3892\/or.2024.8808","volume":"52","author":"H Gui","year":"2024","unstructured":"Gui H, Nie Y, Yuan H, Jing Q, Li L, Zhu L, et al. The combination of a PTP1B inhibitor, TNFR2 blocker, and PD\u20111 antibody suppresses the progression of non\u2011small cell lung cancer tumors by enhancing immunocompetence. Oncol Rep. 2024, Nov;52(5):149. https:\/\/doi.org\/10.3892\/or.2024.8808. Epub 2024 Sep 20. PMID: 39301655; PMCID: PMC11411183.","journal-title":"Oncol Rep"},{"issue":"5","key":"8189_CR31","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.3390\/ijms26051959","volume":"26","author":"Y Li","year":"2025","unstructured":"Li Y, Luo H, Lin X, Hua L, Wang J, Xie J, et al. Triterpenes of prunella vulgaris inhibit triple-negative breast cancer by regulating PTP1B\/PI3K\/AKT\/mTOR and IL-24\/CXCL12\/CXCR4 pathways. IJMS. 2025, Feb, 24;26(5):1959. https:\/\/doi.org\/10.3390\/ijms26051959. PMID: 40076586; PMCID: PMC11900149.","journal-title":"IJMS"},{"key":"8189_CR32","doi-asserted-by":"publisher","unstructured":"Liu Y, Xu Q, Deng F, Zheng Z, Luo J, Wang P, et al. HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway. J Exp Clin Cancer Res. 42(1):38. https:\/\/doi.org\/10.1186\/s13046-023-02609-0. 2023 Feb 1 in: J Exp Clin Cancer Res.2024 Nov 13; 43(1): 300. 10.1186\/s13046-024-03223-4. PMID: 36721234; PMCID: PMC9890722.","DOI":"10.1186\/s13046-023-02609-0"},{"issue":"16","key":"8189_CR33","doi-asserted-by":"publisher","first-page":"21922","DOI":"10.18632\/oncotarget.7829","volume":"7","author":"E Hoekstra","year":"2016","unstructured":"Hoekstra E, Das AM, Swets M, Cao W, van der Woude CJ, Bruno MJ, et al. Increased PTP1B expression and phosphatase activity in colorectal cancer results in a more invasive phenotype and worse patient outcome. Oncotarget. 2016, Apr, 19;7(16):21922\u201338. https:\/\/doi.org\/10.18632\/oncotarget.7829. PMID: 26942883; PMCID: PMC5008334.","journal-title":"Oncotarget"},{"issue":"2","key":"8189_CR34","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3390\/cancers12020500","volume":"12","author":"RA Bartolom\u00e9","year":"2020","unstructured":"Bartolom\u00e9 RA, Mart\u00edn-Regalado \u00c1, Ja\u00e9n M, Zannikou M, Zhang P, de Los R\u00edos V, et al. Protein tyrosine phosphatase-1B inhibition disrupts IL13R\u03b12-promoted invasion and metastasis in cancer cells. Cancers (Basel). 2020, Feb, 21;12(2):500. https:\/\/doi.org\/10.3390\/cancers12020500. PMID: 32098194; PMCID: PMC7072372.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"8189_CR35","doi-asserted-by":"publisher","first-page":"35308","DOI":"10.1038\/srep35308","volume":"6","author":"HW Teng","year":"2016","unstructured":"Teng HW, Hung MH, Chen LJ, Chang MJ, Hsieh FS, Tsai MH, et al. Protein tyrosine phosphatase 1B targets PITX1\/p120RasGAP thus showing therapeutic potential in colorectal carcinoma. Sci Rep. 2016, Oct;6(1):35308. https:\/\/doi.org\/10.1038\/srep35308 in:Sci Rep.2017 Apr 10;7:45612.doi 10.1038\/srep45612. PMID: 27752061; PMCID: PMC5082755.","journal-title":"Sci Rep"},{"issue":"1","key":"8189_CR36","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021, Oct, 11;20(1):131. https:\/\/doi.org\/10.1186\/s12943-021-01428-1. PMID: 34635121; PMCID: PMC8504100.","journal-title":"Mol Cancer"},{"issue":"14","key":"8189_CR37","doi-asserted-by":"publisher","first-page":"11673","DOI":"10.3390\/ijms241411673","volume":"24","author":"Z Zheng","year":"2023","unstructured":"Zheng Z, Wieder T, Mauerer B, Sch\u00e4fer L, Kesselring R, Braum\u00fcller H. T cells in colorectal cancer: unravelling the function of different T cell subsets in the tumor microenvironment. IJMS. 2023, Jul, 19;24(14):11673. https:\/\/doi.org\/10.3390\/ijms241411673. PMID: 37511431; PMCID: PMC10380781.","journal-title":"IJMS"},{"issue":"21","key":"8189_CR38","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.3390\/cancers14215300","volume":"14","author":"S Fang","year":"2022","unstructured":"Fang S, Cheng X, Shen T, Dong J, Li Y, Li Z, et al. CXCL8 up-regulated LSECtin through AKT signal and correlates with the immune microenvironment modulation in colon cancer. Cancers (Basel). 2022, Oct, 28;14(21):5300. https:\/\/doi.org\/10.3390\/cancers14215300. PMID: 36358719; PMCID: PMC9657600.","journal-title":"Cancers (Basel)"},{"key":"8189_CR39","doi-asserted-by":"publisher","unstructured":"Cutilli A, Jansen SA, Paolucci F, van Hoesel M, Frederiks CL, Mulder TAM, et al. Interferon-gamma induces epithelial reprogramming driving CXCL11-mediated T-cell migration. J Leukoc Biol. 2025, Feb, 13;117(2):qiae205. https:\/\/doi.org\/10.1093\/jleuko\/qiae205. PMID: 39302156.","DOI":"10.1093\/jleuko\/qiae205"},{"issue":"1","key":"8189_CR40","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40425-019-0511-6","volume":"7","author":"Q Gao","year":"2019","unstructured":"Gao Q, Wang S, Chen X, Cheng S, Zhang Z, Li F, et al. Cancer-cell-secreted CXCL11 promoted CD8+ T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC. J Immunother Cancer. 2019, Feb, 11;7(1):42. https:\/\/doi.org\/10.1186\/s40425-019-0511-6. PMID: 30744691; PMCID: PMC6371476.","journal-title":"J Immunother Cancer"},{"issue":"13","key":"8189_CR41","doi-asserted-by":"publisher","first-page":"951247","DOI":"10.3389\/fimmu.2022.951247","volume":"13","author":"Y Li","year":"2022","unstructured":"Li Y, Han S, Wu B, Zhong C, Shi Y, Lv C, et al. CXCL11 Correlates with immune infiltration and impacts patient immunotherapy efficacy: a Pan-cancer analysis. Front Immunol. 2022, Jul;13(13):951247. https:\/\/doi.org\/10.3389\/fimmu.2022.951247. PMID: 35935945; PMCID: PMC9355700.","journal-title":"Front Immunol"},{"key":"8189_CR42","doi-asserted-by":"publisher","unstructured":"Jeong H, Koh J, Kim S, Yim J, Song SG, Kim H, et al. Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6\/Jak\/Stat3 in PD-L1-high lung cancer. J Immunother Cancer. 2025, Mar, 6;13(3):e010612. https:\/\/doi.org\/10.1136\/jitc-2024-010612. PMID: 40050048; PMCID: PMC11887297.","DOI":"10.1136\/jitc-2024-010612"},{"issue":"5","key":"8189_CR43","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s42255-024-01037-4","volume":"6","author":"J Wang","year":"2024","unstructured":"Wang J, Yang Y, Shao F, Meng Y, Guo D, He J, et al. Acetate reprogrammes tumour metabolism and promotes PD-L1 expression and immune evasion by upregulating c-Myc. Nat Metab. 2024, May;6(5):914\u201332. https:\/\/doi.org\/10.1038\/s42255-024-01037-4. Epub 2024 May 3. PMID: 38702440.","journal-title":"Nat Metab"},{"issue":"18","key":"8189_CR44","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1182\/blood-2017-11-742577","volume":"131","author":"SC Casey","year":"2018","unstructured":"Casey SC, Baylot V, Felsher DW. The MYC oncogene is a global regulator of the immune response. Blood. 2018, May, 3;131(18):2007\u201315. https:\/\/doi.org\/10.1182\/blood-2017-11-742577. Epub 2018 Mar 7. PMID: 29514782; PMCID: PMC5934797.","journal-title":"Blood"},{"key":"8189_CR45","doi-asserted-by":"publisher","unstructured":"Kang LP, Xie H, Huang HJ, Xu P, Xu C, Huang DH, et al. Pterostilbene inhibits non-small cell lung cancer progression by activating the STING pathway and enhancing antitumor immune response. Front Immunol. 2025, Oct;16;16:1622284. https:\/\/doi.org\/10.3389\/fimmu.2025.1622284. PMID: 41181138; PMCID: PMC12571870.","DOI":"10.3389\/fimmu.2025.1622284"},{"issue":"13","key":"8189_CR46","doi-asserted-by":"publisher","first-page":"1008764","DOI":"10.3389\/fimmu.2022.1008764","volume":"13","author":"L Corrales","year":"2022","unstructured":"Corrales L, Hipp S, Martin K, Sabarth N, Tirapu I, Fuchs K, et al. LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager. Front Immunol. 2022, Sep;13(13):1008764. https:\/\/doi.org\/10.3389\/fimmu.2022.1008764. PMID: 36159851; PMCID: PMC9493073.","journal-title":"Front Immunol"},{"issue":"16","key":"8189_CR47","doi-asserted-by":"publisher","first-page":"1709852","DOI":"10.3389\/fimmu.2025.1709852","volume":"16","author":"X Guo","year":"2026","unstructured":"Guo X, Ma S, Wang J, Fu Y, Ma W. Terminally exhausted CD8+ T cells in solid tumors: biology, biomarker potential and translational tools for precision oncology. Front Immunol. 2026, Jan;16(16):1709852. https:\/\/doi.org\/10.3389\/fimmu.2025.1709852. PMID: 41601689; PMCID: PMC12833282.","journal-title":"Front Immunol"},{"issue":"6","key":"8189_CR48","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41388-024-03223-w","volume":"44","author":"M Zhuang","year":"2025","unstructured":"Zhuang M, Liu J, Li Y, Zhang J, Jiang Z, Wang X, et al. PD-L1 promotes tumor metastasis by regulating the infiltration of FGFBP2(+)Tm cells in colorectal cancer. Oncogene. 2025, Feb;44(6):378\u201390. https:\/\/doi.org\/10.1038\/s41388-024-03223-w. Epub 2024 Nov 18. PMID: 39558101.","journal-title":"Oncogene"},{"issue":"5","key":"8189_CR49","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.cmet.2013.09.013","volume":"18","author":"K Masui","year":"2013","unstructured":"Masui K, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T, et al. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab. 2013, Nov, 5;18(5):726\u201339. https:\/\/doi.org\/10.1016\/j.cmet.2013.09.013. Epub 2013 Oct 17. PMID: 24140020; PMCID: PMC3840163.","journal-title":"Cell Metab"},{"issue":"1","key":"8189_CR50","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1038\/s41467-018-07739-0","volume":"9","author":"M Riddell","year":"2018","unstructured":"Riddell M, Nakayama A, Hikita T, Mirzapourshafiyi F, Kawamura T, Pasha A, et al. aPKC controls endothelial growth by modulating c-Myc via FoxO1 DNA-binding ability. Nat Commun. 2018, Dec, 17;9(1):5357. https:\/\/doi.org\/10.1038\/s41467-018-07739-0. PMID: 30559384; PMCID: PMC6297234.","journal-title":"Nat Commun"},{"key":"8189_CR51","doi-asserted-by":"publisher","unstructured":"Huang Y, Zhang J, Zhu Y, Zhao R, Xie Z, Qu X, et al. BMP9 alleviates iron accumulation-induced osteoporosis via the USP10\/FOXO1\/GPX4 axis. J Adv Res. 2026, Mar;79:S953\u2013972. https:\/\/doi.org\/10.1016\/j.jare.2025.03.012. Epub ahead of print. PMID: 40068762.","DOI":"10.1016\/j.jare.2025.03.012"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08189-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08189-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08189-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T02:20:29Z","timestamp":1781576429000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08189-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8189"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08189-9","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Clinic samples were obtained from Yunnan Cancer Hospital (The Third Affiliated Hospital of Kunming Medical University) and used in accordance with the policies of the institutional review board of the hospital (NO. KYLX2024-101). All animal experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals (8th edition, published by the National Academies Press, Washington, DC, USA), followed the Yunnan Province Regulations on Laboratory Animal Management and approved by the Animal Ethics Committee of Kunming Medical University (Approval No.DWSP202504014).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not commissioned; externally peer reviewed. Generative AI and AI-assisted technologies were NOT used in the preparation of this work","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Provenance and peer review"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"773"}}